Skip to main content
Hana Pharm. Co., Ltd. logo

Hana Pharm. Co., Ltd. — Investor Relations & Filings

Ticker · 293480 ISIN · KR7293480000 KO Manufacturing
Open in API
Filings indexed 243 across all filing types
Latest filing 2024-04-24 Report Publication Anno…
Country KR South Korea
Listing KO 293480

About Hana Pharm. Co., Ltd.

http://www.hanaph.co.kr/eng/index.do

Hana Pharm. Co., Ltd. is a pharmaceutical company engaged in the development, manufacturing, and distribution of a wide range of medical products. The company specializes in anesthetics and narcotic analgesics, establishing a strong position in these therapeutic areas. Its portfolio also encompasses generic drugs, active pharmaceutical ingredients (APIs), antiemetics, and antibiotics. Focused on innovation, Hana Pharm's research and development pipeline includes novel drugs targeting the nervous system. Key projects under development are Byfavo Inj. (remimazolam), an ultra-short-acting anesthetic and sedative, and a new multi-functional MRI contrast agent. The company serves a global market and is expanding its capacity for injectable medicines to meet growing demand.

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최(안내공시)
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 700 characters) notifying the public about an upcoming Investor Relations (IR) event (Non-Deal Roadshow). It provides the date, location, and purpose of the meeting rather than being the presentation material itself. According to the 'Menu vs Meal' rule, an announcement of an event or report is classified as a Report Publication Announcement (RPA) or a general regulatory filing. Given the specific nature of announcing an IR event, it fits best as a Regulatory Filing (RNS) as it is a standard corporate disclosure announcement.
2024-04-24 Korean
[기재정정]기타경영사항(자율공시)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Hana Pharm regarding a 'Correction Report' (정정신고) for a previously disclosed national drug development project. It details the termination of a government-funded research project, providing updated timelines and financial usage figures. Since this is a specific regulatory disclosure regarding corporate management and project status that does not fit into specialized categories like M&A or dividends, it falls under the general regulatory filing category.
2024-04-04 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of a General Meeting of Shareholders (정기주주총회결과) for Hana Pharm. It details the approval of financial statements, dividend declarations, and the election of directors and auditors. This falls under the category of Declaration of Voting Results & Voting Rights Announcements, as it provides the official outcome of the shareholder votes.
2024-03-25 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the appointment and dismissal of outside directors (사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고). This falls under the category of board and management changes, which is classified as MANG.
2024-03-25 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing titled '감사보고서 제출' (Submission of Audit Report) by Hana Pharm. It provides a summary of the audit opinion (unqualified/appropriate) and key financial data (assets, liabilities, revenue, net income) for the fiscal year 2023. While it contains financial data, it is a formal notification of the submission of the audit report to the regulatory body, rather than the full annual report or a standalone audit report document itself. Following the 'Menu vs Meal' rule, this is a notification of a report filing. FY 2023
2024-03-15 Korean
사업보고서 (2023.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for Hana Pharm Co., Ltd. (하나제약 주식회사) for the fiscal year ending December 31, 2023. It includes the independent auditor's report, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes. This is a comprehensive financial audit document, not an earnings release or a summary, and it is clearly the full report rather than an announcement of the report. FY 2023
2024-03-15 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.